dcc-3116
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2021 (NCT04892017)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05957367 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2023 | Deciphera Pharmaceuticals LLC, Pfizer |
| NCT04892017 | Phase 1 | Jun 15, 2021 | Deciphera Pharmaceuticals LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals LLC | For profit | 2 | 2 | 2 | 2021 |
| Pfizer | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1